ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 283

Can Synovial Hypertrophy in the Feet Without Doppler Change During Treatment – Results from a Longitudinal Study of Rheumatoid Arthritis Patients Initiating Biological DMARD

Lene Terslev1, Mikkel Østergaard 2, Joe Sexton 3 and Hilde Hammer 4, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen, Denmark, 2Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, 3Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, 4Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: inflammation and drug treatment, musculoskeletal sonography, Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Imaging Of Rheumatic Diseases Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Ultrasound is used to assess disease activity in rheumatoid arthritis (RA). Gray scale (GS) ultrasound shows the synovial hypertrophy (SH) and Doppler the amount of hyperemia. SH Both with and without Doppler change during treatment in the hands– even grade 1. However, SH grade 1 without Doppler is a common finding in the feet of both RA patients and healthy controls. If low grade SH in metatarsophalangeal joints (MTPs) does not have the ability to change during treatment this should be taken in to consideration in the ultrasound evaluation of disease activity and treatment effect in the feet.
The aim was to investigate if joints with SH without Doppler activity (Doppler negative SH) in MTPs differ in ability to change during treatment with biological DMARD (bDMARD) as compared to metacarpophalangeal joints (MCPs) in RA patients.

Methods: RA patients initiating biological DMARD treatment were included. US examination was performed at baseline, 3 and 6 months using Siemens Antares US equipment with optimized Doppler settings for slow flow. Bilateral MCP 1-5 and MTP 1-5 were evaluated at each visit. SH and Doppler activity were graded from 0-3 according to the US atlas by Hammer et al. The GS score for SH in Doppler negative joints was registered for the individual joints using GS SH >1 as threshold and were compared to changes in SH score in joints with Doppler activity (Doppler positive SH) in both MCPs and MTPs. Doppler positive was defined as Doppler score ≥1.

Results: 157 patients (83.2% women, 81.3% seropositive for anti-CCP and 75.8% for rheumatoid factor) were included, with a mean (SD) age of 51.5 (13.3) years and disease duration of 9.9 (8.1) years. At baseline, 52.2% used prednisolone (mean (SD) 7.7 (4.6) mg, range 2.5-25mg). The patients had a mean (SD) baseline DAS28 of 4.5 (1.5).

1570 MTPs and 1570 MCPs were examined and of these 502 MTPs (32%) had Doppler negative SH and 245 (16%) Doppler positive SH. For MCPs, 251 (16%) had Doppler negative SH and 407(26%) Doppler positive SH. Doppler negative Grade 1 SH were more frequent in MTP than MCP joints and Doppler negative grade 3 SH was rare in MCPs (table 1). The percentage of joints exhibiting a decrease in SH was similar for both MTPs and MCPs, both for joints with Doppler negative SH and Doppler positive SH at baseline. However, adjusting for the grade of SH at baseline, joints with Doppler negative SH appeared to have a somewhat greater tendency towards change. For joints with Doppler negative SH grade 1 at baseline the tendency to change was somewhat lower for MTPs than MCPs (41% vs 63% respectively at 3 months and 43% vs 66% respectively at 6 months follow-up).

Conclusion: Most joints with Doppler negative SH had low grades of SH with the majority having a grade 1 – especially in MTPs. Doppler negative SH in MTPs and MCPs can improve during treatment and exhibit the same tendency to change. For joints with Doppler positive SH, MTPs have the same tendency to change as MCPs except that MTPs with Doppler negative grade 1 SH showed a somewhat lower tendency to change than the corresponding MCPs.

SH=synovial hypertrophy, MCP= metacarpophalangeal joints, MTP=metatarsophalangeal joints


Disclosure: L. Terslev, None; M. Østergaard, AbbVie, 2, 8, 9, Abbvie, 2, 5, 8, Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, UCB, 5, 8, Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB, 5, 8, Abbvie, Celgene, Centocor, Merck, and Novartis, 2, Abbvie, Celgene, Centocor, Merck, Novartis, 2, BMS, 2, 5, 8, 9, Boehringer Ingelheim, 5, 8, Boehringer-Ingelheim, 2, 8, Boehringer-ingelheim, 9, Celgene, 2, 5, 8, Centocor, 2, Eli Lilly, 5, 8, 9, Eli Lilly and Company, 5, 8, Eli-Lilly, 2, 8, Hospira, 2, 5, 8, Janssen, 2, 5, 8, 9, Merck, 2, 5, 8, 9, Novartis, 2, 5, 8, Novo, 2, 5, 8, Novo Nordisk, 5, 8, Orion, 2, 5, 8, Pfizer, 2, 5, 8, 9, Regeneron, 2, 5, 8, Roche, 2, 5, 8, roche, 9, Sandoz, 2, 8, Sanofi, 2, 8, UCB, 2, 5, 8; J. Sexton, None; H. Hammer, None.

To cite this abstract in AMA style:

Terslev L, Østergaard M, Sexton J, Hammer H. Can Synovial Hypertrophy in the Feet Without Doppler Change During Treatment – Results from a Longitudinal Study of Rheumatoid Arthritis Patients Initiating Biological DMARD [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/can-synovial-hypertrophy-in-the-feet-without-doppler-change-during-treatment-results-from-a-longitudinal-study-of-rheumatoid-arthritis-patients-initiating-biological-dmard/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/can-synovial-hypertrophy-in-the-feet-without-doppler-change-during-treatment-results-from-a-longitudinal-study-of-rheumatoid-arthritis-patients-initiating-biological-dmard/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology